Anti-Infectives Restore ORKAMBI<sup>®</sup> Rescue of F508del-CFTR Function in Human Bronchial Epithelial Cells Infected with Clinical Strains of <i>P. aeruginosa</i>
Chronic infection and inflammation are the primary causes of declining lung function in Cystic Fibrosis (CF) patients. ORKAMBI<sup>®</sup> (Lumacaftor-Ivacaftor) is an approved combination therapy for Cystic Fibrosis (CF) patients bearing the most common mutation, F508del, in th...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/10/2/334 |
id |
doaj-6491dc1303054428a423e91470cdbda2 |
---|---|
record_format |
Article |
spelling |
doaj-6491dc1303054428a423e91470cdbda22020-11-25T01:42:27ZengMDPI AGBiomolecules2218-273X2020-02-0110233410.3390/biom10020334biom10020334Anti-Infectives Restore ORKAMBI<sup>®</sup> Rescue of F508del-CFTR Function in Human Bronchial Epithelial Cells Infected with Clinical Strains of <i>P. aeruginosa</i>Onofrio Laselva0Tracy A. Stone1Christine E. Bear2Charles M. Deber3Division of Molecular Medicine, Research Institute, Hospital for Sick Children, Toronto, ON M5G 0A4, CanadaDivision of Molecular Medicine, Research Institute, Hospital for Sick Children, Toronto, ON M5G 0A4, CanadaDivision of Molecular Medicine, Research Institute, Hospital for Sick Children, Toronto, ON M5G 0A4, CanadaDivision of Molecular Medicine, Research Institute, Hospital for Sick Children, Toronto, ON M5G 0A4, CanadaChronic infection and inflammation are the primary causes of declining lung function in Cystic Fibrosis (CF) patients. ORKAMBI<sup>®</sup> (Lumacaftor-Ivacaftor) is an approved combination therapy for Cystic Fibrosis (CF) patients bearing the most common mutation, F508del, in the cystic fibrosis conductance regulator (CFTR) protein. It has been previously shown that ORKAMBI<sup>®</sup>-mediated rescue of CFTR is reduced by a pre-existing <i>Pseudomonas aeruginosa</i> infection. Here, we show that the infection of F508del-CFTR human bronchial epithelial (HBE) cells with lab strain and four different clinical strains of <i>P. aeruginosa,</i> isolated from the lung sputum of CF patients, decreases CFTR function in a strain-specific manner by 48 to 88%. The treatment of infected cells with antibiotic tobramycin or cationic antimicrobial peptide 6K-F17 was found to decrease clinical strain bacterial growth on HBE cells and restore ORKAMBI<sup>®</sup>-mediated rescue of F508del-CFTR function. Further, 6K-F17 was found to downregulate the expression of pro-inflammatory cytokines, interleukin (IL)-8, IL-6, and tumor necrosis factor-α in infected HBE cells. The results provide strong evidence for a combination therapy approach involving CFTR modulators and anti-infectives (i.e., tobramycin and/or 6K-F17) to improve their overall efficacy in CF patients.https://www.mdpi.com/2218-273X/10/2/334cftrcorrectorsantimicrobial peptidetobramycininfectionanti-inflammatory<i>pseudomonas aeruginosa</i>clinical strainsmultidrug resistant bacteria |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Onofrio Laselva Tracy A. Stone Christine E. Bear Charles M. Deber |
spellingShingle |
Onofrio Laselva Tracy A. Stone Christine E. Bear Charles M. Deber Anti-Infectives Restore ORKAMBI<sup>®</sup> Rescue of F508del-CFTR Function in Human Bronchial Epithelial Cells Infected with Clinical Strains of <i>P. aeruginosa</i> Biomolecules cftr correctors antimicrobial peptide tobramycin infection anti-inflammatory <i>pseudomonas aeruginosa</i> clinical strains multidrug resistant bacteria |
author_facet |
Onofrio Laselva Tracy A. Stone Christine E. Bear Charles M. Deber |
author_sort |
Onofrio Laselva |
title |
Anti-Infectives Restore ORKAMBI<sup>®</sup> Rescue of F508del-CFTR Function in Human Bronchial Epithelial Cells Infected with Clinical Strains of <i>P. aeruginosa</i> |
title_short |
Anti-Infectives Restore ORKAMBI<sup>®</sup> Rescue of F508del-CFTR Function in Human Bronchial Epithelial Cells Infected with Clinical Strains of <i>P. aeruginosa</i> |
title_full |
Anti-Infectives Restore ORKAMBI<sup>®</sup> Rescue of F508del-CFTR Function in Human Bronchial Epithelial Cells Infected with Clinical Strains of <i>P. aeruginosa</i> |
title_fullStr |
Anti-Infectives Restore ORKAMBI<sup>®</sup> Rescue of F508del-CFTR Function in Human Bronchial Epithelial Cells Infected with Clinical Strains of <i>P. aeruginosa</i> |
title_full_unstemmed |
Anti-Infectives Restore ORKAMBI<sup>®</sup> Rescue of F508del-CFTR Function in Human Bronchial Epithelial Cells Infected with Clinical Strains of <i>P. aeruginosa</i> |
title_sort |
anti-infectives restore orkambi<sup>®</sup> rescue of f508del-cftr function in human bronchial epithelial cells infected with clinical strains of <i>p. aeruginosa</i> |
publisher |
MDPI AG |
series |
Biomolecules |
issn |
2218-273X |
publishDate |
2020-02-01 |
description |
Chronic infection and inflammation are the primary causes of declining lung function in Cystic Fibrosis (CF) patients. ORKAMBI<sup>®</sup> (Lumacaftor-Ivacaftor) is an approved combination therapy for Cystic Fibrosis (CF) patients bearing the most common mutation, F508del, in the cystic fibrosis conductance regulator (CFTR) protein. It has been previously shown that ORKAMBI<sup>®</sup>-mediated rescue of CFTR is reduced by a pre-existing <i>Pseudomonas aeruginosa</i> infection. Here, we show that the infection of F508del-CFTR human bronchial epithelial (HBE) cells with lab strain and four different clinical strains of <i>P. aeruginosa,</i> isolated from the lung sputum of CF patients, decreases CFTR function in a strain-specific manner by 48 to 88%. The treatment of infected cells with antibiotic tobramycin or cationic antimicrobial peptide 6K-F17 was found to decrease clinical strain bacterial growth on HBE cells and restore ORKAMBI<sup>®</sup>-mediated rescue of F508del-CFTR function. Further, 6K-F17 was found to downregulate the expression of pro-inflammatory cytokines, interleukin (IL)-8, IL-6, and tumor necrosis factor-α in infected HBE cells. The results provide strong evidence for a combination therapy approach involving CFTR modulators and anti-infectives (i.e., tobramycin and/or 6K-F17) to improve their overall efficacy in CF patients. |
topic |
cftr correctors antimicrobial peptide tobramycin infection anti-inflammatory <i>pseudomonas aeruginosa</i> clinical strains multidrug resistant bacteria |
url |
https://www.mdpi.com/2218-273X/10/2/334 |
work_keys_str_mv |
AT onofriolaselva antiinfectivesrestoreorkambisupsuprescueoff508delcftrfunctioninhumanbronchialepithelialcellsinfectedwithclinicalstrainsofipaeruginosai AT tracyastone antiinfectivesrestoreorkambisupsuprescueoff508delcftrfunctioninhumanbronchialepithelialcellsinfectedwithclinicalstrainsofipaeruginosai AT christineebear antiinfectivesrestoreorkambisupsuprescueoff508delcftrfunctioninhumanbronchialepithelialcellsinfectedwithclinicalstrainsofipaeruginosai AT charlesmdeber antiinfectivesrestoreorkambisupsuprescueoff508delcftrfunctioninhumanbronchialepithelialcellsinfectedwithclinicalstrainsofipaeruginosai |
_version_ |
1725036239708487680 |